Stock Events

Stock Events

Atyr Pharma 

$0.81
256
+$0.04+4.61% Today

Statistics

Day High
0.81
Day Low
0.7
52W High
-
52W Low
-
Volume
439
Avg. Volume
-
Mkt Cap
79.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.26
-0.22
-0.17
-0.13
Expected EPS
-0.13125
Actual EPS
N/A

Financials

-27,243.83%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
470,000Revenue
-128.05MNet Income

Analyst Ratings

$17.78Average Price Target
The highest estimate is 33.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATYR.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and inflammatory diseases, similar to aTyr Pharma's focus on immune modulation for various diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen operates in the same biotech space, developing therapies for serious illnesses, including those related to immune system disorders, overlapping with aTyr Pharma's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need, including inflammatory and respiratory diseases, competing with aTyr Pharma's pipeline.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology, autoimmune and hematologic disorders, but its expansion into novel therapeutic areas and biologics can pose competition to aTyr Pharma's novel biologic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals targets serious diseases with its drugs, including cystic fibrosis, which involves managing inflammation and immune response, areas aTyr Pharma is also exploring.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie works on advanced therapies in immunology, oncology, and virology, including treatments for inflammatory diseases, directly competing with aTyr Pharma's focus on immune modulation.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad range of healthcare products in pharmaceuticals, including treatments for autoimmune diseases and inflammation, making it a competitor in the same therapeutic areas as aTyr Pharma.
Pfizer
PFE
Mkt Cap140.15B
Pfizer's wide range of therapeutic areas, including inflammation and immunology, puts it in direct competition with aTyr Pharma, especially with its focus on innovative treatments for diseases.
Merck
MRK
Mkt Cap214.76B
Merck operates in various therapeutic areas, including immunology, and its research into novel therapies for immune-mediated diseases competes with aTyr Pharma's focus.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a diverse portfolio in respiratory, cardiovascular, renal, metabolism, and immunology, including therapies for inflammation and autoimmune diseases, competing with aTyr Pharma's research and development focus.

About

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Show more...
CEO
ISIN
US0021202025

Listings

F
DE
471A.F
BOATS
BOATS
ATYR.BOATS
XNAS
US
LIFE
XNAS
US
ATYR

0 Comments

Share your thoughts

FAQ

What is Atyr Pharma stock price today?▼
The current price of ATYR.BOATS is $0.81 USD — it has increased by +4.61% in the past 24 hours. Watch Atyr Pharma stock price performance more closely on the chart.
What is Atyr Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atyr Pharma stocks are traded under the ticker ATYR.BOATS.
What is Atyr Pharma market cap?▼
Today Atyr Pharma has the market capitalization of 79.15M
When is the next Atyr Pharma earnings date?▼
Atyr Pharma is going to release the next earnings report on May 13, 2026.
What were Atyr Pharma earnings last quarter?▼
ATYR.BOATS earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.18 USD resulting in a +23.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Atyr Pharma revenue for the last year?▼
Atyr Pharma revenue for the last year amounts to 470,000 USD.
What is Atyr Pharma net income for the last year?▼
ATYR.BOATS net income for the last year is -128.05M USD.
When did Atyr Pharma complete a stock split?▼
Atyr Pharma has not had any recent stock splits.